USAMMDA Broad-Spectrum Snakebite Antidote developers take Program Management award during MHSRS

Photo By Cameron Parks | The Honorable Mr. Lester Martinez-Lopez, Assistant Secretary of Defense for Health Affairs, presents the MHSRS and Defense Health Agency Award for Program Management to the U.S. Army Medical Materiel Development Activity’s Broad Spectrum Snakebite Antidote (BSSA) development team as part of the Military Health System Research Symposium, Kissimmee, Florida, Aug. 14, 2023. Kendra Lawrence, Lindsey Garver and Andrea Renner, all leaders with USAMMDA’s Warfighter Protection and Acute Care Project Management Office, and commercial partner Ophirex, Inc., were honored for the BSSA program. They accelerated the technical and programmatic maturity of the critical life-saving drug, varespladib, including two pivotal clinical trials in four years. Their efforts will provide an important capability for warfighters deployed in far-forward, austere conditions where snakebites are a significant threat to life and limb. This team’s drug development effort, funded by the Defense Health Agency, is the direct result of a collaboration between the integrated product team and their small-business partner to identify and mitigate risks early in development and to identify and implement regulatory, financial, contracting, and acquisition planning mechanisms to realize benefits for the program. As the premier developer of world-class military medical capabilities, USAMMDA is responsible for developing and delivering critical drugs, vaccines, biologics, devices and medical support equipment to protect and preserve the lives of Warfighters across the globe. (U.S. Army Photo by Cameron E. Parks/Released)  

KISSIMMEE, FL, UNITED STATES

08.14.2023

Story by T. T. Parish 

U.S. Army Medical Materiel Development Activity (USAMMDA)

The Warfighter Protection and Acute Care (WPAC) Project Management Office (PMO) team was recognized for program management excellence as part of the annual Military Health System Research Symposium in Kissimmee, Florida, Aug. 14.

The WPAC team, part of the U.S. Army Medical Materiel Development Activity at Fort Detrick, Maryland, develops, delivers, and fields U.S. FDA-approved preventions, diagnostics, and treatments to help protect and preserve the lives of U.S. service members.

The WPAC team received the MHSRS and Defense Health Agency award for Program Management for its work to develop a Broad-Spectrum Snakebite Antidote (BSSA).

“This award is a direct reflection of the incredible work of the entire BSSA and WPAC team and I am incredibly proud and humble to be able to lead the men and women who work so hard to address the needs of our Warfighters,” said Kendra Lawrence, Ph. D., the WPAC Project Manager. “The strength of the WPAC team lies in its mission focus, collaborative approach, and vision to help enable combat casualty care capabilities at or near the point of injury. This award symbolizes the dedication of our team in developing and delivering the highest quality medical solutions and capabilities for our men and women in uniform.”

During 2022, the capability to treat snake bite envenoming made a giant leap forward with clinical trial testing under real world conditions and the FDA’s ‘Fast-Track’ designation of Varespladib, a small molecule drug candidate funded by the Defense Health Program and developed in collaboration with a non-Department of Defense partner, according to Lindsey Garver, Ph.D., Deputy Project Manager for WPAC.

“The BSSA program seeks to develop a shelf-stable treatment for snakebite envenoming that is safe, easy to use by individuals in far-forward austere environments, and is independent of snake species,” said Garver. “[Antivenom] is typically species-specific which means you need to know which snake bit you to be treated with the proper antivenom. This also means the military must stock and know how to use multiple types of antivenom to treat bites from different species. There are some species for which no antivenom exists, meaning the only treatment is supportive care. This program seeks to provide a solution to all these issues.”

As U.S. Joint Forces continue to develop expeditionary capabilities for the littoral regions of the Indo-Pacific, where logistics trains must extend across hundreds or thousands of miles, a ready solution to treat service members for snakebite envenomation will place an added tool in medic and corpsmen’s aid bags while higher echelon care is arranged, Garver believes.

“This product is really designed to counter the far-forward threat of snakebites,” said Garver. “There is an inverse relationship as Service Members move into more austere conditions, where the threat of snakebites goes up, and access to higher echelons of care goes down. A successful BSSA product extends easy, effective treatment into those austere conditions, supporting the independent maneuver of small teams and widening the window of time needed for evacuation in the event of a bite.”

While clinical trials are ongoing in the U.S. and India, pre-clinical studies, and the mechanism of action of the BSSA drug suggests it can be used worldwide.

For more information about USAMMDA and how to partner with the U.S. Army medical development enterprises, visit https://usammda.health.mil/.

• Date Taken: 08.14.2023
• Date Posted: 08.14.2023 11:58
• Story ID: 451295
• Location: KISSIMMEE, FL, US